Table 2 Factors associated with ESBL-E acquisition amongst 473 internal medicine patients, University of Geneva Hospitals, March-June 20101; univariate regression analysis
Proportions (n) or Median [range] | Univariate regression | |||
|---|---|---|---|---|
Variable | ESBL acquisition (n = 21) | No ESBL acquisition (n = 452) | OR [95% CI] | P- value |
Male gender | 57.1 (12) | 51.3 (232) | 1.2 [0.51-3.05] | 0.603 |
Transferred from ICU | 28.6 (6) | 8.2 (37) | 4.48 [1.64-12.25 | 0.003 |
Transferred from other ward (other than the ICU) | 14.3 (3) | 2.4 (11) | 6.69 [1.71-26.06] | 0.006 |
Patient admitted from home | 57.1 (12) | 89.4 (404) | 0.16 [0.06-0.39] | <0.001 |
Age (y) | 66.9 [30.6-86.8] | 64.1 [18.8-99.2] | ||
Age | ||||
< = 59 y | 1.45 [0.16-12.90] | 0.737 | ||
60 -79 y | 1.35 [0.16-11.19] | 0.778 | ||
> = 80 y | 1.89 [0.23-15.99] | 0.556 | ||
Length of stay (days) | 12.1 [3–58] | 7.7 [1–54] | ||
Length of stay | ||||
<7 d | 2.69 [0.73-9.95] | 0.138 | ||
7-14 d | 3.09 [0.67-14.23] | 0.146 | ||
14-21 d | 1.5 [0.15-15.13] | 0.718 | ||
>21 d | 25.17 [4.18-151.7] | <0.001 | ||
Acute renal failure2 | 45.4 (5) | 22.7 (45) | 2.83 [0.83-9.71] | 0.098 |
Chronic renal failure2 | 27.2 (3) | 14.6 (29) | 2.12 [0.55-8.72] | 0.268 |
End stage renal failure2 | 0.0 (0) | 3.0 (6) | Omitted | |
Diabetes without complications2 | 9.1 (1) | 18.4 (38) | 0.45 [0.05-3.62] | 0.453 |
Diabetes mellitus (with complications)2 | 9.1 (1) | 11.6 (23) | 0.76 [0.09-6.22] | 0.799 |
Peripheral vascular disease2 | 0.0 (0) | 5.1 (11) | Omitted | |
Chronic obstructive airway disease2 | 18.2 (2) | 21.2 (42) | 0.83 [0.17-3.96] | 0.811 |
Dementia2 | 0.0 (0) | 1.0 (2) | Omitted | |
Stroke2 | 0.0 (0) | 1.0 (2) | Omitted | |
Cerebral hemorrhage2 | 0.0 (0) | 1.0 (2) | Omitted | |
Congestive cardiac failure2 | 9.1 (1) | 25.8 (51) | 0.29 [0.04-2.30] | 0.241 |
Ischemic heart disease2 | 0.0 (0) | 9.6 (19) | Omitted | |
Hematological malignancy2 | 0.0 (0) | 5.1 (11) | Omitted | |
Carotid artery stenosis2 | 0.0 (0) | 2.5 (5) | Omitted | |
Parkinson’s disease2 | 9.1 (1) | 0.5 (1) | 19.70 [1.15-338.43] | 0.040 |
Connective tissue disease2 | 0.0 (0) | 1.0 (2) | Omitted | |
Liver failure2 | 9.1 (1) | 1.0 (2) | 9.80 [0.82-117.39] | 0.072 |
Respiratory failure2 | 0.0 (0) | 0.5 (1) | Omitted | |
Solid organ cancer2 | 18.1 (2) | 14.1 (28) | 1.35 [0.27-6.57] | 0.711 |
Metastatic cancer2 | 0.0 (0) | 6.6 (13) | Omitted | |
Peptic ulcer disease2 | 9.1 (1) | 3.0 (6) | 3.20 [0.35-29.18] | 0.302 |
Infection2 | 0.0 (0) | 0.5 (1) | Omitted | |
Any antibiotic use | 42.9 (9) | 26.5 (120) | 2.08 [0.85-5.04] | 0.108 |
Amoxicillin, flucloxacillin, phenoxymethylpenicillin | 14.3 (3) | 8.6 (39) | 1.76 [0.49-6.25] | 0.379 |
Ceftriaxon | 4.8 (1) | 1.3 (6) | 3.72 [0.43-32.35] | 0.234 |
Cefazolin, cefuroxime | 14.3 (3) | 1.8 (8) | 9.25 [2.22-37.82] | 0.002 |
Macrolide, tetracycline | 0.0 (0) | 1.3 (6) | Omitted | |
Fluoroquinolone | 0.0 (0) | 6.0 (27) | Omitted | |
Ertapenem, imipenem, meropenem | 0.0 (0) | 0.2 (1) | Omitted | |
Cotrimoxazole | 0.0 (0) | 1.3 (6) | Omitted | |
Vancomycin | 4.8 (1) | 0.4 (2) | 11.34 [0.97-129.31] | 0.052 |
Metronidazole | 4.8 (1) | 1.8 (8) | 2.84 [0.33-23.27] | 0.347 |
Gentamicin | 0.0 (0) | 0.3 (1) | Omitted | |